Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients

AIDS

Volumn 18, Issue 11, 2004, Pages 1602-1604

  De Luca, Andrea ^a   Giambenedetto, Simona Di ^a   Cingolani, Antonella ^a   Ammassari, Adriana ^a   Marasca, Giuseppe ^a   Tumbarello, Mario ^a   Fantoni, Massimo ^a   Tamburrini, Enrica ^a   Cauda, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; SUPERINFECTION; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 3843130701     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131365.67704.a4     Document Type: Article

References (9)

1. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzales-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001, 17:1467-1471.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358: 958-965.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
4. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol 2002, 37:500-506.
5. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003, 17:1023-1028.
6. Perronne C, Carrat F, Banisadr F, Morand P, Lunel F, Rosenthal E, et al. ANRS HC02 - Ribavic: a randomized controlled trial of pegylated-interferon alfa-2b with ribavirin vs. Interferon alfa-2a plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 2002 [Abstract H-1083].
7. Chung R, Anderson J, Alston M, Vallee M, Robbins G, Nevin T, et al. A randomised, controlled trial of pegylated Interferon alfa-2a with ribavirin vs interferon alfa-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [Abstract LB15].
8. Berenguer J. Predictive value of early virologic response (EVR) in HIV-infected patients with chronic hepatitis C (CHC) treated with interferon alpha (IFNα) and ribavirin (RBV). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2003 [Abstract V-1726].
9. Brau N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003, 17:2279-2290.